EPALEX Corp filed a Form D with the Securities and Exchange Commission on 2025-11-10.
EPALEX Corp filed a Form D notice of an exempt securities offering with the SEC on November 10, 2025. The filing reports $1.20M sold. Its industry group is Pharmaceuticals. It names Brendan Magrab (Executive Officer, Director), Didric Cedarholm (Director), Randall Murphy (Director) (SEC Form D, November 10, 2025).
Is this your company?
Sell to companies like EPALEX Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-11-10 · the record
Pitching, partnering or investing alongside them? See who really runs and owns EPALEX Corp.
Free to see. No signup.
More on the people and the money behind EPALEX Corp, from the filings we hold.
Pharmaceuticals raises by companies based in California, filed in November 2025, largest first.
Get an email when EPALEX Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when EPALEX Corp raises, hires or launches. No email unless you switch it on.
Watch EPALEX Corp →Get the full cited report on EPALEX Corp
What the filing shows about EPALEX Corp
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on EPALEX Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives EPALEX Corp's address as 1049 El Monte Avenue, Suite C 585, Mountain View, CA 94040.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
EPALEX Corp is a registered filer with the SEC (CIK 1755010) and has filed since 2022-10-14. 3 filings are on record, the latest on 2025-11-10.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
EPALEX Corp's Form D of 2025-11-10 names Brendan Magrab, Didric Cedarholm, Randall Murphy and 2 more as its officers, directors or promoters.
Its new offerings report $9.46M sold across 3 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 155 filings in Pharmaceuticals, totalled by week. The dot is this raise, $1.20M, on the same scale — one filing against the whole group's total, so it sits low by construction.
The proceeds are available to fund general working capital requirements; as of the date of this filing, no detailed operating budget has been adopted; and no proceeds have been or are proposed to be used for payments of finders fees or other compensation.
Brendan Magrab is named as Executive Officer and Director on the Form D that EPALEX Corp filed with the SEC on 10 November 2025, one of 5 people that filing names.
Didric Cedarholm is named as Director on the Form D that EPALEX Corp filed with the SEC on 10 November 2025, one of 5 people that filing names.
Randall Murphy is named as Director on the Form D that EPALEX Corp filed with the SEC on 10 November 2025, one of 5 people that filing names.
Michael Rogawski is named as Director on the Form D that EPALEX Corp filed with the SEC on 10 November 2025, one of 5 people that filing names.
Jon Saxe is named as Director on the Form D that EPALEX Corp filed with the SEC on 10 November 2025, one of 5 people that filing names.
5 people named on the filing — 1 holding an executive role and 4 as directors only.
Named as of the 2025-11-10 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about EPALEX Corp
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on EPALEX Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on EPALEX Corp covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist EPALEX CorpYou get an alert in MentionFox the next time this company shows up.
If you're behind EPALEX Corp: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for EPALEX Corp. With no account yet, you sign up free and land on the result.
On these lists: Pharmaceuticals raises in San Francisco Bay Area
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/epalex-corp-form-d-25000001